IMMUNE SYSTEM RESISTANCE IN NEWBORN BALB/C MICE TREATED WITH 4(3H)-QUINAZOLINONE-2- ETHYL-2-PHENYL ETHYL

Jasem Estakhr, Nasim Javdan

Science and Research Branch, Islamic Azad University, Fars, Iran.

Corresponding Address: Jasem Estakhr, j.estakhr@yahoo.com. Tel: +989179283966

Summary

Quinazolinones are heterocyclic and water insoluble compounds with various pharmacological and biological characteristics (antibacterial, antiswelling, antifungal, parkinson and etc.). They are used for treatment HIV and cancer. This study investigated the effects of 4(3H) quinazlonones-2-ethyl-2-phenyl ethyl (QEPE) as a new quinazolinons compounds on the spleen and immunocompetent cells of newborn Balb/C mice. Pregnant mice were divided into 3 groups (n=10) of control, sham and experimental, received distilled water, methyl cellulose %0.05 (the solvent) and 100 mg/kg Balb/C body weight of QEPE (most effective dose), respectively, by IP injection, on days 8^{th} to 15^{th} of gestation Examinations indicated an increase in weight of spleen in experimental group. Pathological studies showed increase in capsule thickness and number of macrophage cells of experimental group. Statistical analysis showed significance differences in morphological studies between experimental, sham and control groups. The statistical data on capsule thickness and number of macrophage cells indicated significance differences between experimental, sham and control groups. Detailed observations showed increase in the volume of monocyte, neutrophile and eosinophile, in response to QEPE but the volume of lymphocyte and basophile were same in experimental, control and sham groups. The damages caused by this dose of QEPE could have been the reason for the increase in the number of immonucompetent and macrophage cells. Some studies showed damages to the organs such as livers and hearts would lead to the increase in the thickness of spleen capsule, consequently, increase in its weight and creation of splenomegaly. So, QEPE can not be an appropriate candidate for drugs development. Maybe QEPE in the lower dose can be an appropriate candidate for increase of immuno system resistance.

Key Words: Quinazolinones, Immunocompetent cells, Spleen, Balb/C newborn mice.

Introduction

Quinazolinones are heterocyclic and water insoluble compounds (1), with various pharmacological; antimicrobial, antifungal, antitumor, anticonvulsant, anti-inflammatory, antiallergy, antimalaria (2-8). They are more efficient than other chemicals in inhibiting HIV and cancer. They inhibit HIV-1 reverse transcriptase and use for treatment of HIV (9,10). The mechanism of the effects of quinazolinones on the embryonic cells is not clear yet, but there are quite a few reports showing its toxic characteristics. They inhibit polymerization of tubulin (11) and pass through placental barriers (12), so there is a possibility that it has some sort of toxic and teratogenic effects on embryos.

Previous studies at the Department of Zoology, Faculty of Biological Science, University of Shahid-Beheshti, 4(3H) quinazlonones-2-ethyl-2-phenyl ethyl (QEPE) can causes morphological, skeletal and histological abnormalities in Balb/C mice embryos (11-15). In this regard spleen is involved in removed of pathogenic agents and some external components by phagositic cells (macrophage cells) , and some experiments have shown that , alfatoxin , 2-metoxyacetic , 2-metoxyethanol , 2-etoxyethanol , deoxynivalenol , dioxins , ethanol , parachloronitro-benzene and malaria toxins can cause damages and abnormalities in the spleen (16-22). Immunocompetence is vital in maintaining the overall health of an organism and is extremely sensitive to pathogens and toxins (23). Measurement of spleen weight and immunocompetent cells allow evaluation immunopathologic condition of some animals in response to chemical exposure (23-25). We interested that whether treatments pregnant mice with QEPE would affect the spleen morphology and histology and immunocompetent cells of Balb/C mouse fetuses. Corbett et al. (2000) showed that some compounds of quinazolinone are very important in treatment of HIV by inhibiting of reverse transcriptase and increasing of immune system resistance. So, another purpose of this study is, whether this compound is useful for immune system resistance.

Materials and methods

Balb/C mice were housed in 24±1° C ,65 ± 0.5% humidity and lighted controlled room (12h light-dark), provided with lab chow (pellets) and tap water. They were originally obtained from Razi Institute (Tehran, Iran); Random breedings were implemented in our local facility, animal room, with breeding, operation and maintenance sections. Males mated virgin females at overnight, observing vaginal plugs presented day zero of pregnancy. The new derivative of qunazolinones: 4(3H) quinazlonones-2-ethyl-2-phenyl ethyl (QEPE), synthesized at Department of Chemistry, Faculty of Science, University of Shahid-Beheshti, Tehran, Iran (26) were used for IP injection. So, pregnant mice were divided into 3 groups (n=10) of control, sham, and experimental, received distilled water (10ml/kg), methyl cellulose %0.05 (10ml/kg) (the solvent of quinazolinones) and 100 mg/kg Balb/C body weight of QEPE (most effective dose), respectively, by IP injection, on days 8^{th} to 15^{th} of gestation. 5day old newborns were killed by cervical dislocation. The spleen was excised from each mouse and measured in weight. Then they were fixed in formalin %10, stained with H&E (Hematoxilin & Eosine) for histological and pathological studies under compound microscope. For counting of immunocompetent cells, blood samples from the heart were collected by using heparinized tubes. Counting was carried out manually by Neubaur chamber and using Turky's solution (27). Data were analyzed with statistical packages for social sciences (SPSS,version 12.0).Mean and standard error of mean [SEM] were calculated and the significance of difference was analyzed by applying One-Way ANOVA. Level of significance difference was $P<0.05$.

Results

All investigated spleens and immunocompetent cells data are recorded in table 1 and 2. Treatment of mice with 100mg/kg of QPPE can increase weight of spleens (Figs 1-3). There was highly significant increase in spleen weight in experimental group compared the control and sham groups.

Treatment of mice with 100mg/kg QPPE has increased the number of macrophage cells and capsule thickness in spleens (Figs 4-7). There were not significant differences between control and sham groups about number of macrophage cells and capsule thickness, but there are significant differences between experimental group and control and sham groups. Detailed observations showed significant increase in the volume of monocyte, neutrophile and eosinophile, in response to QPPE. Statistical results about the volume of lymphocyte and basophile cells showed no changes in experimental group in compared with control and sham groups.

Discussion

Quinazolinones are heterocyclic, water insoluble and lipophilic compounds, with various pharmacological characteristics; (antimicrobial, antifungal, antiswelling, Parkinson and etc.) (1-8). They are more efficient than other chemicals in inhibiting HIV and cancer (9-11). Xia et al. (2001) displayed quinazolinone as a potent inhibitor of tubulin polymerization. They enter circulatory system and passes through placental barrier (12). With due attention to results of earlier researches and to observe morphological abnormalities, skeletal malformation (13,14) and damage in liver, intestine and kidney (15-17), brain, heart and stomach, we investigate effects of quinazolinones on the spleen development and immunucompetent cells in mouse Balb/C. Results of present study showed that treatment with quinazolinones induce splenomegaly and increase capsule thickness. Measurements of immune-related hematological parameters in mouse blood show that QEPE causes monocytosis, neutrophilia and eosinophilia. Splenomegaly is often seen in hypersplinism, increase of phagocitic cells (especially macrophage cells) and external articles in billroth's cords, patients with hepatic cirrhosis or portal hypertension and damage in liver and heart (22-24, 31,32). Most causes of splenomegaly in this research including: 1-Damage in liver, heart and other organs. 2- Increase of macrophage and immunocompetent cells. Monocytes circulate in the blood stream and differentiate into specific tissue macrophages which are actively phagocytic cells capable of ingesting and digesting exogenous such as the whole bacterial cells, virus particles, and injured or dead host cells (30).Treatments of mice with these components lead to damages in liver, intestine, kidney, heart, stomach and brain. These damages can cause increase in the number of monocyte and macrophage cells. Some experiment have shown that, hyperlipidemia increase the number of macrophage cells in spleen. These macrophage cells interfere in removal of lipid from circulatory system. QEPE causes the increase and fullness of lipid in hepatic hepatocytes (17). It appears that QEPE disorders the metabolism of lipids and create hyperlipidemia. Also, these tow compound can cause neurophilia and eosinophilia. It is possible that, QEPE can increases migration of eosinophils and neutrophils from bone marrow to the blood stream. Eosinophils, like neutrophils, are motile, phagocytic cells that can migrate from the blood into the tissue spaces. Their phagocytic role is less important than that of neutrophils, and it is thought that their major role consists in defense against parasitic organisms (30). However, neutrophils are the first cells that arrive at a site of inflammation during response to many types of infection. Before investigations had shown that these two compounds can cause necrosis in some organs such as; intestine, kidney (15,16) heart and stomach. While creation of necrosis increase white blood cells, macrophage cells and defensive factors.

Increase of splenic capsule thickness is often seen in patients with hepatic cirrhosis or portal hypertension from other causes and in liver and heart (31). Other causes of splenic capsular thickening are increase of matrix contents and increase of blood cells and macrophage cells (32). In this study it is probable that most cause of splenic capsular thickening are caused by damages in liver and heart, and increase of macrophage cells. We concluded that Treatments of mice with these components lead to damages in liver, intestine, kidney, heart, stomach and brain. These damages can cause increase in the number of immonucompetent and macrophage cells. Some studies have shown that damage in liver and heart lead to increase of capsule thickness. Indeed this factor causes increase in weight and leads to splenomegaly. Therefore, QEPE cannot be an appropriate candidate for drugs development. Maybe QEPE in the lower dose can be an appropriate candidate for increase of immune system resistance.

Table 1: Effects of 100 mg/kg of QPPE on the spleen of newborn Balb/C mice.

Parameters	Control	Sham	Experimental
Spleen Weight	0.04178 ± 0.0002	0.04185 ± 0.0001	0.04557 ± 0.0005*
Macrophage Cells	159.03 ± 2.53	158.8 ± 1.56	490.93 ± 2.37*
Capsule Thickness (μm)	2.98 ± 0.061	2.98 ± 0.03	4.65 ± 0.037*

Values are mean ± SEM (n=10); *P < 0.05 (significantly different) vs. control and sham groups

Table 2: Effects of 100 mg/kg of QEPE on the immunocompetent cells of newborn Balb/C mice.

Parameters	Control	Sham	Experimental
Lymphocyte	67.47 ± 0.184	67.48 ± 0.189	67.49 ± 0.088
Monocyte	2.35 ± 0.022	2.36 ± 0.013	2.84 ± 0.017*
Neutrophile	29.64 ± 0.049	29.64 ± 0.046	30.10 ± 0.046*
Eosinophile	2.45 ± 0.012	2.44 ± 0.012	2.56 ± 0.008*
Basophile	0.36 ± 0.0057	0.36 ± 0.0078	0.36 ± 0.0061

Values are mean ± SEM (n=10); *P < 0.05 (significantly different) vs. control and sham groups

Figure1: Normal spleen of control group that treated with 10 ml/kg body weight of distilled water (6X).

Figure2: Normal spleen of sham group that treated with 10 ml/kg body weight of methyl cellulose %0.05 (6X).

Figure3: The spleen of experimental group that treated with 100 mg/kg body weight of QEPE, in which splenomegaly were observed (6X).

Figure4: Normal spleen capsule of control group that treated with 10 ml/kg body weight of distilled water (H&E, 400X).



Figure5: Normal spleen capsule of sham group that treated with 10 ml/kg body weight of methyl cellulose %0.05 (H&E, 400X).



Figure6: Increase of spleen capsule of experimental group that received with 100 mg/kg body weight of QPPE (H&E, 400X).



Figure7: Cross section of spleen of treated group with 100 mg/kg body weight of QPPE, having large number of macrophage cells (arrows, H&E, 1000X).



References

1- David, J, Declan, C, Timothy, S. and Patrick, J. (2005): Synthesis of quinazolinones and quazolines. Tetrahedron 61(43), 10153-202.
2- James, F. W., Terry, L. R., Mark, C. S. and Thomes, F. W. (1990): Synthesis and anticonvulsant activity of some new substituted 3- aryl – 4(3) – quinazolinones. J. Med. Chem. 33, 161-66.
3- Pines, M., Vlodavsky, I. and Nagler, A. (2000): Halofuginone: from veterinary use to human therapy. Drug Develop. Res. 50(3-4), 371-78.
4- Buyuktimkin, S., Ekinci, A. C., Buyuktimkin, N. and Otuk, G. (2006): Pharmacological studies on quaternized 4(3*H*)-quinazolinones. J. Pharm. Sci. 81(11), 1092-94.
5- Jatav, V., Jain, S. K., Kashaw, S. K. and Mishra, P. (2006): Synthesis and antimicrobial activity of novel 2-methyl-3-(1'3'4'-Thiadiazoyl)-4-(3h) quinazolinones. Indian J. Pharmaceut. Sci. 68(3), 360-63.
6- Yesilada, A., koyunoglu, S., Saygilia, N., Kupeli, E., Yesilida, E., Bedir, E. and Khanc, I. (2004): Synthesis,anti inflammatory and analgesic activity of some new4(3H)-quinazolinones derivatives. Archiv. Der. Pharmazie. 337(2), 96-104.
7- Ouyang, G., Zahng, P., Xu, G., Song, B., Jin, L., Xue, W., Hu, D., Lu, P., and Chen, Z. (2006): Synthesis and antifungal bioactivities of 3-alkylquinazolin-4-one derivatives. Molecules 11, 383-92.
8- Baek, D. J., Kang, T. B., and Kim H. J. (2004): Synthesis of nonclassical quinazolinone antifolates as thymidylate synthase inhibitors and their antitumor activity in vitro. B. Kor. Chem. Soc. 25(12), 1896-906.
9- Corbett, J. W., Ko, S., Rodgers, J. D. and Erickson, S. K. (2000). Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone nonnucleoside reverse transcriptase inhibitors. J. Med. Chem. 43, 2019-30.
10- Boumendjel, A., Baubichon-Cortay, H., Trompier, D., Perrotton, T. and Di Pietro, A. (2005): Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents. Med. Res. Rev. 25(4), 453 – 72.
11- Mann, J., Li, H., Kuo, L. and Sheng, C. (2006): 6-Alkylamino and 2,3 Dihydro-3- methoxy-2-phenyl-4-quinazolinones and related compounds: Their synthesis, cytotoxicty and inhibition of tubulin polymerization. J. Med. Chem. 43(23), 4479-87.

12- Perretti, L. and Zilletti, L. (1969): Transplacental of methyl-o-tolyl-quinazolinone in rat. Riv. Stet. Ginecol. 24(1), 1-11.
13- Shams lahijani, M., Ahmadzadeh, F. and Dabiri, M. (2006): Teratogenic effects of new quinazolinone derivative on the development of Balb/C mice fetuses on days 9, 10 and 11 of gestation. Iran. J. Sci. Technol. 30A1, 1-8.
14- Shams lahijani, M. and Aounegh R. (2007): Teratogenic effect of quinazolinone on Balb/C mice fetuses. JMSR. 1 (1), 25-30.
15- Etemad, S. and Shams Lahijani, M. (2007, 21-25 April): Quinazolinones and nerphrotoxicity in new born Balb/C mice. 7th World Congress of Nephrology (WCN), Rio de Janeiro, Brazil.
16- Fadavi, M. and Shams Lahijani, M. (2007, 15-19 July): Pathological effects of quinazolinones on the small intestine of new born Balb/C mouse. XI International Congress of Toxicology (ICT), Montreal, Canada.
17- Rajabi, H. and Shams Lahijani, M. (2007, 15-19 July): Histological study of liver of newborn Balb/C mice treated with quinazolinones. XI International Congress of Toxicology (ICT), Montreal, Canada.
18- Jimenez, V., Cardinal, D. P., Alvarez, M. P. and Boggiov, A. L. (2005): Effect of chronic ethanol feeding on 24-hour rhythms of mitogenic responses and lymphocyte subset populations in spleen of peripubertal male rats. Neuroimmunomodulat 12, 357-65.
19- Sehu, A., Erqun, L., Cakir, S. and Sahin, T. (2007): Hydrated sodium calcium aluminosilicate for reduction of alfatoxin in quails. Toxicology 114(7), 252-59.
20- Riddle, M. M., Williams, W. C. and Smialowicz, R. J. (1996): Methoxyacetic suppress humoral immunity in the mouse. Toxicology 109(1), 67-74.
21- Matsumoto, M., Aiso, S., Senoh, H. and Matsushima, T. (2006): Chronic toxicity of para-chloronitrobenzene in rats. Environ. Pathol. Toxicol. Oncol. 25(3), 571-75.
22- Sama, R. and Moro, P. (1993): NTP technical report on the toxicity studies of the Glycol Ethers: 2-methoxyethanol and 2-ethoxyethanol. J. Med. Chem. 16(23), 479-87.
23- Paula, M., William, B. B. and Wanda, M. H. (1998): Preventation of T-2toxin-induced morphologic effects in the rat by highly activated charcoal. Toxicology 117(11), 459-64.
24- Bordmann, G., Favre, N. and Rudin, W. (1997): Malaria Toxin: Effects on murine spleen and bone marrow cell proliferation and cytokine production in vitro. Parasitology 115, 475-83.
25- Institoris, L., Siroki, O., Undeger, U., Basaran, N., Banerjee, B. D. and Desi, I. (2001): Detection of the effects of repeated dose combined propoxur and heavy metal exposure by measurement of certain toxicological, haematological and immune function parameters in rats. Toxicology 163, 185-93.
26- Keith, A. G. (2002): Assessing immunological function in toxicological studies of avian wildlife. Integr. Comp. Biol. 42, 34-42.
27- Jennifer, A. B., Laura, A. V., Joel, B., Brain, H. and Sabine, S. L. (2004): Effect of heavy metals on immunocompetence of white-footed mice (Peromyscus leucopus). J. Wildl. Dis. 40(2), 173-84.
28- Dabiri, M., Salehi, P., Khajavi, M. S. and Mohammadi, A. (2004): Microw ae-assisted one-pot three component synthesis of some new 4(3H)-quinazolinone derivatives. Heterocycles 63(6), 1417-21.
29- Brecher, M., Harbaugh, C. and Pineda, A. (1992): Accurate counting of low numbers of leukocytes: use of flow cytometry and manual low-count chamber. Am. J. Clin. Pathol. 97, 872-75.
30- Richard, A. J., Thomas, J. K., Barbara, A. O. and Janis, K. (1997): Immunology. W. H. Freeman and Company. New York.
31- Wanless, I. R. and Bernier, V. (1983): Fibrous thickening of the splenic capsule. A response to chronic splenic congestion. Arch. Pathol. Lab. Med. 107(11), 595-99.
32-Radovan, B. (1987): Splenic fibrosis in patients with chronic schistosomiasis.Mem. Inst. Oswaldo Cruz, Rio de Janeiro 82, 253-55.
33- Xia, Y., Yang, Z. Y., Hour, M. J., Kuo, S. C., Xia, P., Bastow, K. F., Nakanishi, Y., Nampoothiri, P., Hackl, T., Hamelc, E., and Lee, K. H. (2001): Antitumor agents. Part 204. 1: Synthesis and biological evaluation of substituted 2-aryl quinazolinones. Bioorg. Med. Chem. Lett. 11, 1193-96.